PMC:7795856 / 3845-4102 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"116","span":{"begin":183,"end":186},"obj":"Gene"},{"id":"117","span":{"begin":237,"end":243},"obj":"Gene"},{"id":"125","span":{"begin":151,"end":159},"obj":"Species"},{"id":"131","span":{"begin":223,"end":233},"obj":"Chemical"},{"id":"138","span":{"begin":142,"end":150},"obj":"Disease"}],"attributes":[{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Gene:134864"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Gene:1493"},{"id":"A125","pred":"tao:has_database_id","subj":"125","obj":"Tax:9606"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:D000074324"},{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"MESH:D008545"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"boosts therapeutic efficacy [15]. Indeed, a retrospective study evaluating clinical phase II data reported an increase in overall survival of melanoma patients receiving sequentially Tα1 and the immune checkpoint inhibitor ipilimumab, a CTLA-4-blocking anti"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":142,"end":150},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002861"}],"text":"boosts therapeutic efficacy [15]. Indeed, a retrospective study evaluating clinical phase II data reported an increase in overall survival of melanoma patients receiving sequentially Tα1 and the immune checkpoint inhibitor ipilimumab, a CTLA-4-blocking anti"}